Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of C? and the variable framework regions of the VL gene K104 with J? -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons.
Synagis is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. Thimerosal or other mercury-containing salts are not used in the production of Synagis. The solution has a pH of 6.0 and should appear clear or slightly opalescent.
Each 100 mg single-dose vial of Synagis liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg), in a volume of 1 mL.
Each 50 mg single-dose vial of Synagis liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 mL.
Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
The following point
should be considered when prescribing Synagis:
- Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and childrenÂ with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies (14)].
- The safety and efficacy of Synagis have not been established for treatment of RSV disease.
Published Studies Related to Synagis (Palivizumab)
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. [2011.08]
Children with hemodynamically significant congenital heart disease (CHD) are at risk for serious respiratory syncytial virus (RSV) disease. This study was designed to assess the safety and tolerability of motavizumab versus palivizumab in children with CHD and was not powered for efficacy... Safety and efficacy were consistent with another study comparing motavizumab with palivizumab in premature infants without CHD.
Tetracaine (ametop) compared to placebo for reducing pain associated with intramuscular injection of palivizumab (synagis). [2009.12]
Infants receive many painful immunizations before they are 2 years old. The purpose of this study was to evaluate if topical tetracaine reduces the pain of intramuscular palivizumab compared to placebo...
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. [2007.07]
OBJECTIVE: Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing... CONCLUSIONS: Our study suggests that preventing RSV LRTI with palivizumab may reduce subsequent recurrent wheezing in premature infants.
Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. [2007.04]
OBJECTIVE: Palivizumab, a monoclonal antibody against respiratory syncytial virus (RSV), has been demonstrated to be safe and effective in young children, but evidence is lacking as to whether palivizumab is effective in preventing RSV-induced morbidity and mortality in children who are immunosuppressed after bone marrow transplantation (BMT). As a randomized, double-blind, placebo-controlled trial is lacking, we chose to examine this issue with the use of decision analysis methodology... CONCLUSIONS: Decision analysis modeling demonstrates a decrease in mortality in pediatric BMT patients with the addition of palivizumab to protect against RSV-related lung disease. A well-designed, randomized controlled trial is necessary.
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. [2005.11]
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations.
Clinical Trials Related to Synagis (Palivizumab)
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection [Completed]
Published data by the Organización panamericana de la Salud shows that Peru's mortality rate
from acute respiratory infections (ARI) in infants less than one year of life is second only
to Haiti (14,150/100,000). Government data reports shows a marked increase of RSV infections
in Peru. "Instituto Nacional de Salud" (Peru's National Institute of Health) reports between
January 1st to February 26th 2006, 62% of their positive samples corresponded to RSV.
Epidemiological data from Lima-Peru, demonstrates that there is no specific season for RSV
infection although some data suggest an increase in RSV activity during cold months (May to
September; INS data). Clinical studies show that giving five doses of Synagis (palivizumab)
resulted in serum concentrations > 30 ug/mL for >20 weeks. The aim of this post-marketing
observational study is to determine the RSV hospitalization rate in high-risk infants who
received Synagis (palivizumab) through the Social Security Hospitals in the context of
routine clinical practice.
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children [Completed]
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or
with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as
prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the
safety and efficacy of the drug in Russian subjects.
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) [Completed]
The purpose of this study is to measure the rate of anti-palivizumab antibodies (also
referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid
or lyophilized formulation of palivizumab. This study will compare the number and percentage
of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized
formulation of palivizumab.
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season [Completed]
This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and
palivizumab were administered sequentially to high-risk children during the same respiratory
syncytial virus (RSV) season. A control group was administered only motavizumab.
Compliance to Synagis (Palivizumab) Under Daily PediatricianÂ´s Conditions in Premature Infants 33 - 35 wGA [Completed]
Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against
respiratory syncytial virus (RSV) infection as shown in the IMpact study. Many factors such
as parents' knowledge of burden of respiratory syncytial virus disease or physicians'
satisfaction with Synagis as well as the appropriate use of the product might influence
compliance. The primary objective of this observational study is to evaluate the compliance
to Synagis under daily pediatricians practice conditions in premature infants 33 to 35 weeks
gestational age (wGA). Palivizumab, monoclonal antibody for passive immunoprophylaxis
against severe respiratory syncytial virus disease, was administered according to usual
clinical practice. Compliance was assessed using four criteria: The number of injections
per participant per respiratory syncytial virus season, the body site where injections were
administered, the interval in days between injections, and the dosage per administration.
Originally the study was to include two respiratory syncytial virus seasons but was extended
to a third season.
Reports of Suspected Synagis (Palivizumab) Side Effects
Viral Infection (65),
Hypophagia (62), more >>
Page last updated: 2011-12-09